Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Investor Presentation (August 2024)
16 slides from Scorpius's investor presentation, August 2024
Slide 1: Investor Presentation – August 2024
A Rapidly Growing, Highly Scalable Biologics Contract Development & Manufacturing Organization (CDMO) Investor Presentation – August 2024 NYSE American: SCPX
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes statements that are, or may be deemed, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, these forward-looking statements can be identified by the use of forward-loo
Slide 3: Full-Service CDMO Focused on Biologic Production for the Middle Market
Full-Service CDMO Focused on Biologic Production for the Middle Market Scorpius seeks to differentiate itself from competitors with a comprehensive mix of service offerings and a nimble, “boutique” approach to project planning and execution 3
Slide 4: Investment Highlights
Investment Highlights ➢ Pure-play biologics CDMO offering a comprehensive range of services from process and analytical development through clinical-stage and small-scale commercial cGMP manufacturing ➢ Growing demand for Contract Development & Manufacturing Organization (CDMO) services and signific
Slide 5: Leadership Team
Leadership Team Joe Payne Jeff Wolf Bill Ostrander President and Chief Founder & CEO Chief Financial Officer Operating Officer 30+ Years Of Experience 20+ Years Of Experience 20+ Years Of Experience Avigen, TyRx Pharma, Elusys KBI, Liquidia Technologies, Alcami, Tergus, Teva Elusys Matt LeClair Bria
Slide 6: Growing Market Due to Rising Demand and Expanding Treatment Scope
Growing Market Due to Rising Demand and Expanding Treatment Scope Scorpius is positioned to take advantage of rapid growth of the biopharmaceutical market now with a rising demand for biologics and the aging global population What Are Biopharmaceuticals? Global Biologics Market Size (2022 - 2032)* B
Slide 7: Increased Biologic Demand Driving Rapid Growth in CDMO Segment
Increased Biologic Demand Driving Rapid Growth in CDMO Segment Large Molecule Drug Substance CDMO Market size is poised to grow from $10.86B in 2022 to $21B by 2030, growing at a CAGR of 8.6% in the forecast period (2023-2030)* Over the last decade, R&D spending has steadily shifted from its focus o
Slide 8: Business History
Business History In the two years since breaking ground, Scorpius is currently executing on a diverse pipeline of CDMO contracts Q1’24: Substantial pipeline with Nov ’20: Scorpius Oct ’22: Opened San preparation for first GMP BioManufacturing is founded Antonio facility batches underway Worked with
Slide 9: Manufacturing Snapshot
Manufacturing Snapshot Brand new, state-of-the-art 40,000+ sq. ft. campus with mammalian / cell therapy / microbial manufacturing / analytical development / QC process development capability Clinical-scale biomanufacturing in San Antonio, TX located in the heart of a thriving innovation district Hig
Slide 10: Supported Drug Modalities
Supported Drug Modalities Scorpius, with its mammalian and microbial platforms, will compete in two market segments: ➢ Biodefense ($16.1B market in 2023, growing at CAGR of 5.0% to reach $22.3B market by 2030)* ➢ Biopharmaceuticals ($389B market in 2021, growing at CAGR 7.1% to reach $720B by 2030)*
Slide 11: BioMap and BIOSECURE ACT Foster US Production of Advanced Biologics
BioMap and BIOSECURE ACT Foster US Production of Advanced Biologics The BIOSECURE Act (“the Act”), would prohibit executive agencies from contracting with any company with commercial arrangements with a “biotechnology company of concern” which generally means a company that is headquartered in or su
Slide 12: Summary Statement of Operations
Summary Statement of Operations Developments: Six Months Twelve Months Ended Ended ➢ Approximately $70M in total expenditures developing Scorpius’ CDMO June 30, 2024 December 12, 2023 business since inception, including approx. $35M of direct facility investment (PP&E, etc.) Revenue $4,273,892 $6,99
Slide 13: Balance Sheet
Balance Sheet Pro-Forma As of June 30, 2024: As of June 30, 2024 1 ➢ Only term debt is the convertible promissory note of $2.25M, maturing 9/1/2025 (Fair value = $1.94M) Cash and Short-Term Investments $14,272,112 ➢ Conversion price is $22.00 per share Total Current Assets 16,220,412 ➢ Microbial fac
Slide 14: Laser-Focused on Driving Revenue and Cash Flow
2024 Goals ➢ Deliver seamless execution on signed manufacturing contracts ➢ Expand pipeline with target biotech, pharma, and research customers ➢ Streamline operations to deliver at scale ➢ Bolster and strengthen in-house development and analytical services ➢ Develop talent and culture, creating a t
Slide 15: Summary
Summary ➢ Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical-scale manufacturing capacity within the industry ➢ Scorpius began 2023 with $3M of signed manufacturing contracts, which has grown to over $18M in signed manu
Slide 16: Media and Investor Relations Contact
Media and Investor Relations Contact David Waldman [email protected] 16
Scorpius Holdings — Investor Presentation (August 2024) on 6ix